ERBB2 and breast cancer: Additionally, they found that PDPN+CAFs enriched in trastuzumab-resistant tumor tissues and promoted trastuzumab resistance in HER2+ breast cancer by secreting immunosuppressive factors, thereby inhibiting ADCC mediated by functional NK cells.